-
Synthetic Controls for Implementation Science: Opportunities for HIV Program Evaluation Using Routinely Collected Data Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-03-13 Sara Wallach, Suzue Saito, Harriet Nuwagaba-Biribonwoha, Lenhle Dube, Matthew R. Lamb
-
HIV-1 Myeloid Reservoirs — Contributors to Viral Persistence and Pathogenesis Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-02-27
Abstract Purpose of Review HIV reservoirs are the main barrier to cure. CD4+ T cells have been extensively studied as the primary HIV-1 reservoir. However, there is substantial evidence that HIV-1-infected myeloid cells (monocytes/macrophages) also contribute to viral persistence and pathogenesis. Recent Findings Recent studies in animal models and people with HIV-1 demonstrate that myeloid cells are
-
Complex Decisions in HIV-Related Cryptococcosis: Addressing Second Episodes of Cryptococcal Meningitis Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-02-24 Abdu Musubire, Enock Kagimu, Timothy Mugabi, David B. Meya, David R. Boulware, Nathan C. Bahr
-
Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-01-26
Abstract Purpose of Review Selection of antiretroviral therapy during pregnancy must consider maternal physiology and resulting pharmacokinetic changes in pregnancy, resistance and efficacy profiles, tolerability and frequency of adverse effects, teratogenicity, and maternal, neonatal, and pregnancy outcomes. The objective of this review is to summarize the underlying data that informs the current
-
Central Nervous System Complications of HIV in Children Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-01-22 Hanalise V. Huff, Kristen Sportiello, David R. Bearden
-
Major Drug Resistance Mutations on Reverse Transcriptase Gene in Human Immunodeficiency Virus Type-1 in Indonesia: A Systematic Review Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-01-20 Nurjannah, Sri Jayanti, Francisca Srioetami Tanoerahardjo, Ummu Syauqah Al Musyahadah, Caecilia Hapsari Ceriapuri Sukowati, Muhammad Nasrum Massi
-
More than the Infinite Monkey Theorem: NHP Models in the Development of a Pediatric HIV Cure Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2024-01-16 Jairo A. Fonseca, Alexis C. King, Ann Chahroudi
-
Digital Interventions to Enhance PrEP Uptake and Adherence Through Stigma Reduction Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-12-07 Jane J. Lee, Juliann Li Verdugo, Anna Y. Xiao, Katie Vo
Purpose of Review Although pre-exposure prophylaxis (PrEP) is effective for reducing risk of HIV transmission, stigma persists as a barrier to HIV prevention. Digital technologies present opportunities to access hard-to-reach populations and increase the efficiency of established interventions. This review examines current digital interventions addressing stigma to improve PrEP-related outcomes. Recent
-
Awareness of Heightened Sexual and Behavioral Vulnerability as a Trigger for PrEP Resumption Among Adolescent Girls and Young Women in East and Southern Africa Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-12-05 Krishnaveni Reddy, Thesla Palanee-Phillips, Renee Heffron
-
The Role of p53 in HIV Infection Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-27 Mahmoud Mohammad Yaseen, Nizar Mohammad Abuharfeil, Homa Darmani
-
Chatbots for HIV Prevention and Care: a Narrative Review Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-27 Alastair van Heerden, Shannon Bosman, Dallas Swendeman, Warren Scott Comulada
-
Mpox and HIV—Collision of Two Diseases Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-23 Jason Zucker, Aniruddha Hazra, Boghuma K. Titanji
-
Ongoing Healthcare Disparities in neuroHIV: Addressing Gaps in the Care Continuum Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-24 Dan Tong Jia, Paloma M. Carcamo, Monica M. Diaz
Purpose of Review We aim to review the neurological complications of HIV and the social, cultural, and economic inequalities that contribute to disparities in neuroHIV care. Recent Findings Disparities in diagnostics and care of patients with neurological infections and non-infectious conditions associated with HIV in both high-income and low-to-middle-income countries (LMIC) are common. The COVID-19
-
Overamped: Stimulant Use and HIV Pathogenesis Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-16 Emily J. Ross, Renessa S. Williams, Michael Viamonte, John M. Reynolds, Dustin T. Duncan, Robert H. Paul, Adam W. Carrico
-
Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-13 Fengting Wu, Francesco R. Simonetti
-
Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-10 Sarah Kimuda, Derrick Kasozi, Suzan Namombwe, Jane Gakuru, Timothy Mugabi, Enock Kagimu, Morris K. Rutakingirwa, Kristoffer E. Leon, Felicia Chow, Sean Wasserman, David R. Boulware, Fiona V. Cresswell, Nathan C. Bahr
-
Genomic Exploration of the Brain in People Infected with HIV—Recent Progress and the Road Ahead Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-10 Amara Plaza-Jennings, Schahram Akbarian
-
Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2 Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-11 Ferron F. Ocampo, Pathariya Promsena, Phillip Chan
-
Paradata: Measuring Engagement in Digital HIV Interventions for Sexual and Gender Minorities Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-06 Seul Ki Choi, Kathryn E. Muessig, Lisa B. Hightow-Weidman, José A. Bauermeister
-
Digital Adaptive Behavioral Interventions to Improve HIV Prevention and Care: Innovations in Intervention Approach and Experimental Design Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-04 Inbal Nahum-Shani, Sylvie Naar
-
Digital Epidemiological Approaches in HIV Research: a Scoping Methodological Review Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-02 Lindsay E. Young, Yuanfeixue Nan, Eugene Jang, Robin Stevens
-
Pharmacological and Behavioral Interventions to Mitigate Premature Aging in Patients with HIV Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-11-02 Roxane Rohani, Jacob Malakismail, Emmanuel Njoku
Purpose of Review We sought to review pharmacological and behavioral interventions that have been publicly presented, published, or are currently ongoing to prevent or mitigate the effect of premature HIV-associated comorbidities. Recent Findings Multiple studies have been conducted in hopes of finding an effective intervention. While the choice of antiretroviral regimen influences recovery of immune
-
Fatty Liver Disease: Enter the Metabolic Era Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-10-26 Kara Wegermann, Cynthia Moylan, Susanna Naggie
-
Strategies for Hepatitis B Virus Prevention in People Living with HIV Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-10-14 Maria A. Corcorran, H. Nina Kim
-
Challenges and Solutions to STI Control in the Era of HIV and STI Prophylaxis Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-09-26 Felix Ong’era Mogaka, Jenell Stewart, Victor Omollo, Elizabeth Bukusi
Purpose of Review This article reviews current efforts to control bacterial sexually transmitted infections (STIs) among HIV pre-exposure prophylaxis (PrEP) users and outlines the opportunities and challenges to controlling STIs within HIV PrEP programs. Recent Findings The incidence of STIs continues to rise globally especially among HIV PrEP users, with an estimated 1 in 4 PrEP users having a curable
-
Intervention Approaches to Address Intimate Partner Violence and HIV: a Scoping Review of Recent Research Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-09-28 Kamila A. Alexander, Gloria Mpundu, Brenice Duroseau, Nkemakolem Osian, Shadae Chambers, DaJaneil McCree, Karin E. Tobin, Tiara C. Willie
-
The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-09-21 Melanie C. Goebel, Emmanuel Guajardo, Thomas P. Giordano, Shital M. Patel
Purpose of Review Despite the availability of safe and effective oral combination antiretroviral therapy, barriers to maintaining viral suppression remain a challenge to ending the HIV epidemic. Long-acting injectable antiretroviral therapy was developed as an alternative to daily oral therapy. This review summarizes the current literature on the efficacy of long-acting cabotegravir plus rilpivirine
-
Integrated Care Models: HIV and Substance Use Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-09-12 Katherine Hill, Irene Kuo, Sheela V. Shenoi, Mahalia S. Desruisseaux, Sandra A. Springer
-
Spiraling Risk: Visualizing the multilevel factors that socially pattern HIV risk among gay, bisexual & other men who have sex with men using Complex Systems Theory Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-07-24 K. Stojanovski, E. J. King, S. O’Connell, K. S. Gallagher, K. P. Theall, A. T. Geronimus
-
Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-06-21 Smritee Dabee, Christina Balle, Maricianah Onono, Steve Innes, Gonasagrie Nair, Thesla Palanee-Phillips, Adam D. Burgener, Steven E. Bosinger, Jo-Ann S. Passmore, Renee Heffron, Heather Jaspan, Anna-Ursula Happel
-
Interventions to Improve Adolescent HIV Care Outcomes Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-06-10 Marta I. Mulawa, Elizabeth T. Knippler, Maryam Al-Mujtaba, T. Harper Wilkinson, Venkata K. Ravi, Leila S. Ledbetter
-
Interventions to Reduce Alcohol Use and HIV Risk among Sexual and Gender Minority Populations: a Systematic Review Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-05-25 Carolyn Lauckner, Kimberly Haney, Fidelis Sesenu, Trace Kershaw
-
A Review of Serious Gaming as an Intervention for HIV Prevention Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-05-22 Ariel U. Smith, Gabriella M. Khawly, Janna Jann, Ana Paola Mata Zetina, Janeth Padilla, Rebecca Schnall
-
Mpox and HIV: a Narrative Review Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-05-13 Carlos S. Saldana, Colleen F. Kelley, Bruce M. Aldred, Valeria D. Cantos
-
Implementing Geospatial Science and Technology to Get to Zero New HIV Infections Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-05-05 Enbal Shacham, Stephen E. Scroggins, Matthew Ellis
Purpose of Review Tremendous advancements have been made in HIV treatment and prevention during the last 40 years that zero new HIV cases has become an attainable goal declared by international agencies. However, new cases of HIV infection persist. Recent Findings The emerging field of geospatial science is positioned to play key role in the reduction of continued HIV incidence through technology-driven
-
The human microbiome and gut–liver axis in people living with HIV Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-05-02 Maria J. Duarte, Phyllis C. Tien, Ma Somsouk, Jennifer C. Price
-
Reporting Individual-Level Research Results from Neurocognitive and Psychological Research in People Living with HIV: Lessons from Dementia Research Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-04-19 Holly L. Peay, Stuart Rennie, Gail E. Henderson
Purpose of Review There are growing expectations for the return of individual-level research results (RoR), which promotes autonomy and potential clinical and personal benefits. There are ethical and practical challenges, however, that may be exacerbated in research that assesses neurocognitive and psychological outcomes, including HIV-associated neurocognitive disorder (HAND). This paper reviews central
-
Ethical Perspectives in Using Technology-Enabled Research for Key HIV Populations in Rights-Constrained Settings Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-04-06 Lidia Flores, Sean D. Young
Purpose of Review People who use illicit drug substances (e.g., heroin) and sex workers are vulnerable to acquiring HIV. Due to the criminalization of illicit drug substances and sex work in many countries, these populations often reside in rights-constrained settings where their well-being, freedom, and access to HIV prevention and care services may be compromised due to legal prosecutions and societal
-
Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-04-04 Arjee Restar, Brian J. Minalga, Ma. Irene Quilantang, Tyler Adamson, Emerson Dusic, Leigh-Ann van der Merwe, Greg Millet, Danvic Rosadiño, Tanya Laguing, Elle Lett, Avery Everhart, Gregory Phillips, Rena Janamnuaysook, Pich Seekaew, Kellan Baker, Florence Ashley, Jeffrey Wickersham, Stephaun E. Wallace, Don Operario, Kristi E. Gamarel
-
HIV Reservoir: How to Measure It? Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-04-01 Xinyu Zhang, Jun Chen
-
Sustaining HIV Research in Resource-Limited Settings Using PLAN (People, Learning, Adapting, Nurturing): Evidence from the 4 Youth by Youth Project in Nigeria Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-03-29 Juliet Iwelunmor, Joseph D. Tucker, Oliver Ezechi, Ucheoma Nwaozuru, Chisom Obiezu-Umeh, Titilola Gbaja-Biamila, David Oladele, Adesola Z. Musa, Collins O. Airhihenbuwa
-
The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-03-27 Lanbo Yang, Mary Catherine Cambou, Karin Nielsen-Saines
Purpose of Review The goal of this review is to highlight and interpret recent trends and developments in the diagnosis, treatment, and prevention of HIV vertical transmission from a clinical perspective. Recent Findings Universal third-trimester retesting and partner testing may better identify incident HIV among pregnant patients and result in early initiation of antiretroviral therapy to prevent
-
Update on Central Nervous System Effects of HIV in Adolescents and Young Adults Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-02-21 Jennifer L. McGuire, Judith B. Grinspan, Kelly L. Jordan-Sciutto
-
The Gut Microbiome, Microbial Metabolites, and Cardiovascular Disease in People Living with HIV Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-01-28 Brandilyn A. Peters, Robert D. Burk, Robert C. Kaplan, Qibin Qi
Purpose of Review To synthesize recent evidence relating the gut microbiome and microbial metabolites to cardiovascular disease (CVD) in people living with HIV (PLWH). Recent Findings A few cross-sectional studies have reported on the gut microbiome and cardiovascular outcomes in the context of HIV, with no consistent patterns emerging. The largest such study found that gut Fusobacterium was associated
-
Updates on HIV and Kidney Disease Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-01-25 C. Elena Cervantes, Mohamed G. Atta
-
Biological Aging in People Living with HIV on Successful Antiretroviral Therapy: Do They Age Faster? Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-01-25 Sara Svensson Akusjärvi, Ujjwal Neogi
-
Advances in HIV Research Using Mass Cytometry Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-01-23 Ashley F. George, Nadia R. Roan
-
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-01-21 Matteo Augello, Valeria Bono, Roberta Rovito, Camilla Tincati, Giulia Marchetti
-
Evidence for Implementation: HIV/HCV Coinfection and Pregnancy Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2023-01-18 Megan Rose Curtis, Catherine Chappell
Purpose of Review In the context of the opioid epidemic, hepatitis C virus (HCV) infection prevalence is increasing among women of reproductive age. Pregnant people with HIV/HCV coinfection may be at increased risk of adverse pregnancy and neonatal outcomes, although research in this key population is lacking. Recent Findings Treatment with directly acting antivirals (DAAs) has transformed the clinical
-
Does Voluntary Medical Male Circumcision Reduce HIV Risk in Men Who Have Sex with Men? Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-12-15 Yidie Lin, Yanxiao Gao, Yue Sun, DeAnne Turner, Huachun Zou, Sten H. Vermund, Han-Zhu Qian
Purpose of Review To review the evidence on the effect of voluntary medical male circumcision (VMMC) on reducing HIV risk among men who have sex with men (MSM) and assess the limitations of available evidence. Recent Findings Individual studies have shown conflicting results, but recent meta-analyses have consistently suggested that VMMC was associated with 7 to 23% reductions in HIV prevalence or
-
Voluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-12-07 Sten H. Vermund
Purpose of Review This commentary introduces the special Global Health Section on the state of voluntary medical male circumcision (VMMC) programs and current knowledge as to role of VMMC prevention of HIV infection acquisition in men and, indirectly, women. Recent Findings Since the first clinical trial of VMMC in Africa was published in 2005, implementation of programs has depended on illuminating
-
Understanding the Evolving Role of Voluntary Medical Male Circumcision as a Public Health Strategy in Eastern and Southern Africa: Opportunities and Challenges Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-12-02 Anna Bershteyn, Edinah Mudimu, Ingrida Platais, Samuel Mwalili, James E. Zulu, Wiza N. Mwanza, Katharine Kripke
-
VMMC Programmatic Successes and Challenges: Western Kenya Case Study Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-29 Kawango Agot, Jacob Onyango, Marylyn Ochillo, Elijah Odoyo-June
Purpose of Review The Nyanza region of western Kenya is lauded for impressive coverage of voluntary medical male circumcision (VMMC) and remains the bedrock of the VMMC program in Kenya. We conducted literature review on programmatic successes and challenges of implementing VMMC program in the region. Recent Findings Responsive stakeholders’ engagement, robust policy environment, effective technical
-
Diabetes in HIV: the Link to Weight Gain Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-23 Samuel S. Bailin, John R. Koethe
Purpose of Review The burden of metabolic diseases, including type 2 diabetes mellitus (T2DM), is rising among persons with HIV (PWH) on antiretroviral therapy (ART). This increase coincides with an aging population and a greater proportion who are overweight/obese. This review summarizes the changing epidemic of T2DM on contemporary ART, the role of weight gain, and therapeutic options. Recent Findings
-
Defining the Global Research and Programmatic Agenda and Priority Actions for Voluntary Medical Male Circumcision for HIV Prevention Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-11 Megan E. Peck, Todd Lucas, Katherine S. Ong, Jonathan M. Grund, Stephanie Davis, Aisha Yansaneh, Valerian L. Kiggundu, Anne G. Thomas, Kelly Curran, Catharine Laube, Maaya Sundaram, Wole Ameyan, Lycias Zembe, Carlos Toledo
-
The Effects of Medical Male Circumcision on Female Partners’ Sexual and Reproductive Health Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-11 Supriya D. Mehta
-
Risk Compensation in Voluntary Medical Male Circumcision Programs Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-09 Yanxiao Gao, Yinghui Sun, Weiran Zheng, Yi-Fan Lin, Tian Tian, Yuwei Li, Leiwen Fu, Huachun Zou
Purpose of Review Evidence from clinical trials identified the effectiveness of voluntary medical male circumcision (VMMC) as an additional strategy to reduce the risk of HIV transmission from women to men. However, concerns about post-circumcision sexual risk compensation may hinder the scale-up of VMMC programs. We reviewed the evidence of changes in risky sexual behaviors after circumcision, including
-
Consolidated Overview of Notifiable Adverse Events in the U.S. President’s Emergency Plan for AIDS Relief’s Voluntary Medical Male Circumcision Program Through 2020 Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-08 Todd Lucas, Caroline Cooney, Amber Prainito, Catherine Godfrey, Valerian Kiggundu, Anne Goldzier Thomas, Renee Ridzon, Carlos Toledo
Purpose of Review Through December 2020, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) supported more than 25 million voluntary medical male circumcisions (VMMC) as part of the combined HIV prevention strategy in 15 African countries. PEPFAR monitors defined adverse events (AEs) occurring within 30 days of VMMC through its notifiable adverse event reporting system (NAERS). All NAERS
-
Voluntary Medical Male Circumcision for HIV Prevention: a Global Overview Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-11-08 Chen Zhang, Sten H. Vermund
-
How Does Voluntary Medical Male Circumcision Reduce HIV Risk? Curr. HIV/AIDS Rep. (IF 4.6) Pub Date : 2022-10-29 Jessica L. Prodger, Ronald M. Galiwango, Aaron A. R. Tobian, Daniel Park, Cindy M. Liu, Rupert Kaul
Purpose of Review Voluntary medical male circumcision (VMMC) is a surgical procedure that reduces HIV acquisition risk by almost two-thirds. However, global implementation is lagging, in part due to VMMC hesitancy. A better understanding of the mechanism(s) by which this procedure protects against HIV may increase acceptance of VMMC as an HIV risk reduction approach among health care providers and